Rozwój wtórnej ostrej białaczki szpikowej w populacji komórek Ph– z monosomią chromosomu 7 u chorego z przewlekłą białaczką szpikową w fazie przewlekłej

Elżbieta Patkowska(Institute for Transfusion Medicine), Krzysztof Warzocha(Instytut Hematologii i Transfuzjologi), Monika Prochorec‐Sobieszek(Instytut Hematologii i Transfuzjologi), Przemysław Juszczyński(Instytut Hematologii i Transfuzjologi), Iwona Solarska(Instytut Hematologii i Transfuzjologi), Katarzyna Borg
Unknown
October 18, 2011
Cited by 0

Related Papers

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|390
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy
|Blood|2022|129
SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism
|Cell Death and Disease|2020|41
Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)
|Leukemia & lymphoma/Leukemia and lymphoma|2017|39
Targeting the thioredoxin system as a novel strategy against B‐cell acute lymphoblastic leukemia
|Molecular Oncology|2019|37